BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

U.S. drugmaker Pfizer and German biotech BioNTech said they began their late-stage human trial for a potential coronavirus vaccine on Monday as pharmaceutical companies race to win regulatory approval before the end of the year.

Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday

NEW YORK and MAINZ, Germany, July  27, 2020  (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program, against SARS-CoV-2.

Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study

MAINZ, Germany, July  27, 2020  (GLOBE NEWSWIRE) --  BioNTech SE  (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the closing of its previously announced underwritten offering (the “Underwritten Offering”) of 5,500,000 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $93.00 per ADS, for gross proceeds of approximately $512 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioNTech. In addition, a selling shareholder granted the underwriters a 30-day option to purchase up to 825,000 additional ADSs at the same public offering price, which has not yet been exercised. BioNTech would not receive any of the proceeds from such a sale of ADSs by the selling shareholder.

BioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares

AstraZeneca

Inovio Pharmaceuticals

Moderna

Novavax

Let's take a look at what's happened so far and what's on the horizon.

Here's Your Guide to the Coronavirus Vaccine Leaders

One coronavirus vaccine candidate in phase 3 testing might have the best shot at achieving commercial success.

5 Late-Stage COVID-19 Vaccines: Which Is Likely to Be the Biggest Winner?

President Trump Thinks This Coronavirus Vaccine Candidate Is a Winner

Vaxart

COVID-19 vaccines might not be the moneymakers investors are hoping for.

Why Moderna, Vaxart, Inovio, and BioNTech Stocks Dropped Today

GlaxoSmithKline

It was the press announcement heard around the world: a potential Covid-19 vaccine from the University of Oxford and pharmaceutical company AstraZeneca had not only been “tolerated” by patients, but “generated robust immune responses against the Sars-CoV-2 virus in all evaluated participants”. The project will now proceed to all-important phase 3 trials in Brazil and South Africa to test if it actually stops infection.

Covid-19 is Big Pharma’s chance to impress. But who’ll do best?

MAINZ, Germany, July  23, 2020  (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the pricing of its previously announced underwritten offering and terms of its previously announced rights offering.

BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) and its German partner BioNTech struck a $1.95 billion deal with the U.S.

What we know from Pfizer’s deal with the U.S. government

Pharmaceutical company to deliver 100m doses of vaccine but US could buy another 500m under agreement, Alex Azar said

US agrees to pay Pfizer $2bn for Covid-19 vaccine doses by end of year

Washington will pay $1.95 billion to the companies for 100 million doses of their SARS-CoV-2 vaccine -- if it passes muster.

Pfizer and BioNTech Ink Deal with U.S. Government for Big Coronavirus Vaccine Purchase

Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

Pfizer and BioNTech Set to Receive a Sweet Payoff for COVID-19 Vaccines

The vaccine could be available as early as October.

Pfizer Gets $1.95 Billion U.S. Deal For 100 Million Doses Of Planned Covid-19 Vaccine

Pfizer and BioNTech scored a deal with the U.S. government Wednesday for up to 600 million doses of their coronavirus vaccine.

Pfizer, BioNTech Score $2 Billion Deal For Coronavirus Vaccine In U.S.

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) have announced the award of another contract to supply their jointly-developed coronavirus vaccine candidate that's currently in Phase 1/2 development.

Pfizer, BioNTech To Supply US Government 600M Doses Of Coronavirus Vaccine

The feds placed a $2 billion order for 100 million doses of Pfizer’s potential coronavirus vaccine under the Trump administration’s push to have a shot ready by next year. Americans would receive Pfizer’s shots for free under the deal announced Wednesday — assuming the vaccine it’s developing with the German biotech firm BioNTech wins federal.

Feds order 100 million doses of Pfizer’s COVID-19 vaccine for $2 billion

BioNTech BNTX, +3.85% and Pfizer Inc. PFE, +0.52% said they will receive $1.95 billion from the U.S.

BioNTech, Pfizer shares gain on U.S. funding for coronavirus vaccine doses

The vaccine is being jointly developed by German biotech firm BioNTech and U.S.-based Pfizer.

U.S. government taps Pfizer to produce millions of doses of coronavirus vaccine

NEW YORK and MAINZ, Germany, July  22, 2020  (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration (FDA).

Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S.

Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

New research could mean the market opportunity for COVID-19 vaccines might be bigger than expected. Or maybe not.

Could These Findings Dramatically Change the Opportunities for COVID-19 Vaccine Stocks?

Coronavirus vaccine maker BioNTech announced a public offering early Tuesday, leading BNTX stock to pop for the third day running. Pfizer could buy additional shares of BNTX stock
The post Why Top-Notch Coronavirus Stock BioNTech Surged For A Third Day appeared first on Investor's Business Daily.

Why Top-Notch Coronavirus Stock BioNTech Surged For A Third Day

BioNTech S.E. (NASDAQ: BNTX) has been one of the leading companies in the race to a COVID-19 vaccine.

BioNTech Raises Over $400 Million to Boost COVID-19 Efforts

Attaining a new fast-track designation for a vaccine is often beneficial for a company’s shareholders in the short term, but it also implies intensified organizational and scientific challenges.

News for BioNTech SE Stock (BNTX)